glp-1 agonist and dpp-4 inhibitor DPP4 Mechanism of Action – My Endo Consult Mechanism of action for GIP,
Description
This enhanced effectiveness is likely linked to Mounjaros dual-action mechanism, targeting both GLP-1 and GIP receptors, which may provide a more comprehensive metabolic benefit

Advertisement With this dual agonism, tirzepatide has demonstrated the largest weight loss in a randomized trial of any medication for obesity/overweight to date, with its highest dose achieving a 22.5% reduction relative to placebo at 72 weeks in the phase 3 SURMOUNT-1 trial ( N Engl J Med

But it is still not a simple one-size-fits-all substitution

2 They are also associated with a significant potential to lower A1C

Rodriguez PJ et al

These findings underscore the enhanced therapeutic potential of dual incretin receptor activation in achieving robust and sustained metabolic improvements
